Cipla Ltd

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Cipla's US subsidiary is recalling 1,875 boxes of Lanthanum Carbonate chewable tablets due to complaints of broken tablets, as reported by the USFDA.

Cipla Recalls Lanthanum Carbonate Tablets in US - 21 Nov, 2024

Cipla is recalling over 1,800 boxes of Lanthanum Carbonate chewable tablets in the US due to reports of broken tablets. The recall is classified as Class II, indicating potential temporary health risks.

Cipla Recalls Lanthanum Carbonate Due to Defects - 20 Nov, 2024

Cipla has allotted 17,064 equity shares under its Employee Stock Option Scheme 2013-A and Stock Appreciation Rights Scheme 2021, increasing its paid-up share capital to Rs 1,61,52,25,016.

Cipla Allocates Equity Shares Under ESOS - 15 Nov, 2024

Cipla's Bengaluru manufacturing facility received eight observations from the USFDA following an inspection. The company is committed to addressing these observations promptly.

Cipla Faces USFDA Observations at Bengaluru Facility - 14 Nov, 2024

Cipla Ltd announced it received eight observations from the US FDA following an inspection of its Bengaluru facility. The company is committed to addressing these observations promptly. Despite a strong quarterly profit report, shares fell 1.3% on the news.

Cipla Faces FDA Observations After Inspection - 13 Nov, 2024

Cipla's CEO Umang Vohra expresses confidence in the company's growth trajectory, citing opportunities from the biosecurity act and government health programs. Despite temporary supply disruptions and a high base effect, Cipla anticipates 10-12% growth in India, supported by a robust product pipeline and FDA compliance efforts.

Cipla Confident in Growth Despite Temporary Challenges - 11 Nov, 2024

Cipla is addressing slow seasonal growth in its One India business while managing supply issues with generic Lanreotide. The company anticipates recovery in Q4 FY25. Analysts maintain an ACCUMULATE rating with a target price of INR 1,680/share, reflecting confidence in future growth.

Cipla Targets Growth Amid Supply Challenges - 05 Nov, 2024

Cipla's stock surged following the USFDA's VAI classification of its Goa facility, enhancing prospects for drug launches like gAbraxane. Brokerages upgraded ratings, citing growth potential despite existing challenges. The stock closed up 1.63% on November 4, 2024.

Cipla Stock Rises on Positive FDA Goa Facility News - 04 Nov, 2024

Cipla shares jumped nearly 10% following the USFDA's Voluntary Action Indicated (VAI) status for its Goa facility, alleviating regulatory concerns and paving the way for new product launches, including a generic version of Abraxane. The stock's positive momentum reflects market confidence in Cipla's growth potential in the oncology segment.

Cipla Shares Surge After USFDA VAI Status - 31 Oct, 2024

Cipla reported a 15% increase in net profit for Q2, but faced challenges including weak domestic sales and supply issues. Analysts cut target prices, leading to a decline in share price. UBS and other brokerages express concerns over future growth prospects.

Cipla Faces Challenges Despite Q2 Profit Growth - 30 Oct, 2024

Cipla's Q2 results show a 17% net profit increase to ₹1,303 crore, despite regulatory delays affecting key drug launches. Promoter Kamil Hamied returns to the board.

Cipla Reports Strong Q2 Results Amid Challenges - 29 Oct, 2024

Analysts anticipate Cipla's Q2FY25 results to show low single-digit growth in sales and profit, with net profit expected at Rs 1,174 crore, a 1.55% YoY increase. Revenue may rise 4.1% YoY to Rs 6,957 crore, but margins could be impacted by lower US sales. Overall, a 3% YoY growth in sales is projected.

Cipla Q2 Preview Indicates Modest Growth - 28 Oct, 2024

Cipla has successfully completed the acquisition of an additional 6.9% equity interest in Cipla Jiangsu Pharmaceuticals, making it a wholly owned step-down subsidiary as of October 25, 2024.

Cipla Completes Acquisition of Stake in Cipla Jiangsu - 25 Oct, 2024

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Netprofit is up for the last 3 quarters, 939.04 Cr → 1.30K Cr (in ₹), with an average increase of 14.9% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Revenue is up for the last 3 quarters, 6.41K Cr → 7.24K Cr (in ₹), with an average increase of 5.9% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Foreign Institutions have increased holdings from 27.77% to 28.74% in Sep 2024 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

In the last 7 days, CIPLA stock has moved up by 1.5%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

In the last 1 year, Divis Laboratories Ltd has given 62.6% return, outperforming this stock by 35.6%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 128.6% return, outperforming this stock by 65.4%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Promoters holdings remained unchanged at 30.86% of holdings in Sep 2024 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Retail Investor have decreased holdings from 16.30% to 16.08% in Sep 2024 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Mutual Funds have decreased holdings from 17.59% to 17.44% in Sep 2024 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

NIFTY PHARMA

BSE 100

S&P BSE SENSEX 50

BSE MFG

NIFTY 100

NIFTY 50

S&P BSE 100 LargeCap TMC

S&P BSE Dividend Stability

S&P BSE 100 ESG

Nifty100 Low Volatility 30

Nifty 200

Nifty LargeMidcap 250

BSE 500

BSE Healthcare

S&P BSE AllCap

Nifty 500

S&P BSE Largecap

BSE 200

Nifty Healthcare

Nifty100 Eq Weig

S&P BSE 250 LargeMidCap

HDFC Flexi Cap Fund -Direct Plan - Growth Option

HDFC ELSS TaxSaver -Direct Plan - Growth Option

Parag Parikh Flexi Cap Direct Growth

Kotak Flexicap Fund Direct Growth

HDFC Focused 30 Fund -Direct Plan - Growth Option

Cipla Ltd’s net profit jumped 15.18% since last year same period to ₹1,302.53Cr in the Q2 2024-2025. On a quarterly growth basis, Cipla Ltd has generated 10.61% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	0.08	Bearish
CCI (20)	-482.16	Bullish
RSI (14)	53.82	Neutral
Momentum (10)	0	Bullish
ADI (14)	21.89	Neutral
Ultimate Oscillator (7,14,28)	76.12	Bullish

Name	Value	Action
SMA (20)	295.89	Bullish
EMA (20)	295.76	Bullish
VWMA (20)	295.9	Bullish
SMA (50)	295.68	Bullish
EMA (50)	295.62	Bullish
SMA (200)	294.24	Bullish
EMA (200)	294.38	Bullish
KAMA (200)	295.31	Bullish
DEMA (200)	296.12	Bearish

MOIL Ltd (MOIL)

Summary

Overall

Oscillators

Moving Averages